Project Details
Description
A Phase 3, 2-Part, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects Aged 6 to 11 Years with Cystic Fibrosisand the G551D Mutation
Status | Finished |
---|---|
Effective start/end date | 10/8/09 → 9/30/13 |
Funding
- VERTEX PHARMACEUTICALS INCORPORATED
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.